These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 19098390)

  • 1. Basic and translational research on proteinase-activated receptors: antagonism of the proteinase-activated receptor 1 for thrombin, a novel approach to antiplatelet therapy for atherothrombotic disease.
    Chintala M; Shimizu K; Ogawa M; Yamaguchi H; Doi M; Jensen P
    J Pharmacol Sci; 2008 Dec; 108(4):433-8. PubMed ID: 19098390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanism of action and clinical development of platelet thrombin receptor antagonists.
    Ueno M; Ferreiro JL; Angiolillo DJ
    Expert Rev Cardiovasc Ther; 2010 Aug; 8(8):1191-200. PubMed ID: 20670195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thrombin receptor antagonism -the potential of antiplatelet medication SCH 530348.
    Macaulay TE; Allen C; Ziada KM
    Expert Opin Pharmacother; 2010 Apr; 11(6):1015-22. PubMed ID: 20307225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral antiplatelet therapy for atherothrombotic disease: current evidence and new directions.
    White HD
    Am Heart J; 2011 Mar; 161(3):450-61. PubMed ID: 21392598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving antiplatelet therapy for atherothrombotic disease: preclinical results with SCH 530348, the first oral thrombin receptor antagonist selective for PAR-1.
    Hildemann SK; Bode C
    Hamostaseologie; 2009 Nov; 29(4):349-55. PubMed ID: 19882073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging oral antiplatelet therapies for acute coronary syndromes.
    Pollack CV
    Hosp Pract (1995); 2010 Nov; 38(4):29-37. PubMed ID: 21068524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial.
    Morrow DA; Scirica BM; Fox KA; Berman G; Strony J; Veltri E; Bonaca MP; Fish P; McCabe CH; Braunwald E;
    Am Heart J; 2009 Sep; 158(3):335-341.e3. PubMed ID: 19699854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protease-activated receptor-1 antagonists: focus on SCH 530348.
    Sugunaraj JP; Mehta V; Kalra A; Sukhija R; Palaniswamy C
    Am J Ther; 2012 Nov; 19(6):465-9. PubMed ID: 21248619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vorapaxar: a novel protease-activated receptor-1 inhibitor.
    Gurbel PA; Jeong YH; Tantry US
    Expert Opin Investig Drugs; 2011 Oct; 20(10):1445-53. PubMed ID: 21819272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SCH-530348, a thrombin receptor (PAR-1) antagonist for the prevention and treatment of atherothrombosis.
    Oestreich J
    Curr Opin Investig Drugs; 2009 Sep; 10(9):988-96. PubMed ID: 19705342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protease-activated receptor-1 antagonists in long-term antiplatelet therapy. Current state of evidence and future perspectives.
    Moschonas IC; Goudevenos JA; Tselepis AD
    Int J Cardiol; 2015 Apr; 185():9-18. PubMed ID: 25777282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role for Thrombin Receptor Antagonism With Vorapaxar in Secondary Prevention of Atherothrombotic Events: From Bench to Bedside.
    Moon JY; Franchi F; Rollini F; Angiolillo DJ
    J Cardiovasc Pharmacol Ther; 2018 Jan; 23(1):23-37. PubMed ID: 28565918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral antiplatelet therapy for atherothrombotic disease: overview of current and emerging treatment options.
    Fintel DJ
    Vasc Health Risk Manag; 2012; 8():77-89. PubMed ID: 22393298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibiting PAR-1 in the prevention and treatment of atherothrombotic events.
    Tomasello SD; Angiolillo DJ; Goto S
    Expert Opin Investig Drugs; 2010 Dec; 19(12):1557-67. PubMed ID: 20979570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platelet thrombin receptor antagonism and atherothrombosis.
    Angiolillo DJ; Capodanno D; Goto S
    Eur Heart J; 2010 Jan; 31(1):17-28. PubMed ID: 19948715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of an orally available PAR-1 antagonist as a novel antiplatelet agent.
    Lee S
    Arch Pharm Res; 2011 Apr; 34(4):515-7. PubMed ID: 21544715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Platelet biology and implications for antiplatelet therapy in atherothrombotic disease.
    Montalescot G
    Clin Appl Thromb Hemost; 2011 Aug; 17(4):371-80. PubMed ID: 20566574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of platelet activation: need for new strategies to protect against platelet-mediated atherothrombosis.
    Jennings LK
    Thromb Haemost; 2009 Aug; 102(2):248-57. PubMed ID: 19652875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vorapaxar in the secondary prevention of atherothrombosis.
    Tantry US; Liu F; Chen G; Gurbel PA
    Expert Rev Cardiovasc Ther; 2015 Dec; 13(12):1293-305. PubMed ID: 26559689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vorapaxar, a Protease-Activated Receptor-1 Antagonist, a Double-Edged Sword!
    Bhandari B; Mehta B
    Recent Adv Cardiovasc Drug Discov; 2014; 9(2):73-7. PubMed ID: 26104312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.